. Author manuscript; available in PMC: 2025 Feb 1.

Published in final edited form as: J Pediatr Gastroenterol Nutr. 2023 Dec 27;78(2):261–271. doi: 10.1002/jpn3.12074

Table 4.

The combined effect of lower infliximab level and detectable Antibodies to Infliximab (ATI) on the risk of infliximab discontinuation.

		Univariate		Multivariate^a
		HR(95%CI)	P value	HR(95%CI)	P value
Undetectable ATI ^b
Infliximab≥5.0 μg/mL	12/145	1.00		1.00
Infliximab<5.0 μg/mL	5/38	1.84(0.65-5.26)	0.25	2.30(0.71-7.51)	0.17
Detectable ATI ^b
Infliximab≥5.0 μg/mL	3/12	2.62(0.74-9.30)	0.14	3.65(0.95,13.96)	0.06
Infliximab<5.0 μg/mL	11/24	6.68(2.88-15.46)	<0.001	6.07(2.26-16.32)	<0.001

Adjusted for Age (continuous), sex, Body Mass Index (continuous), combination therapy (never, prior, current), CRP>0.5 mg/dL (yes/no), albumin (continuous) and IBD type (CD or UC)

Detectable Antibodies To Infliximab >3.1 U/mL undetectable <3.1U/mL